0.65Open0.65Pre Close0 Volume878 Open Interest310.00Strike Price0.00Turnover54.70%IV22.75%PremiumDec 20, 2024Expiry Date0.00Intrinsic Value100Multiplier19DDays to Expiry0.65Extrinsic Value100Contract SizeAmericanOptions Type0.0600Delta0.0038Gamma326.54Leverage Ratio-0.0989Theta0.0074Rho19.60Eff Leverage0.0684Vega
Alnylam Pharmaceuticals Stock Discussion
Alnylam Highlights New Data From HELIOS-B Study of Vutrisiran for the Treatment of Transthyretin Amyloidosis With Cardiomyopathy at Heart Failure Society of America Annual Scientific Meeting 2024 | ALNY Stock News
ALNY BUY ALERT 🚨 DRUG NEWS MULTIPLE PRICE TARGET RAISES
No comment yet